ALDX Company Profile and Key Details

Q: Who are the executives of ALDX?

Mr. Kelly MizerVice President of Commercial Strategy & OperationsDr. Todd C. Brady M.D., Ph.D.Chief Executive Officer, Pres & DirectorDr. Stephen G. Machatha Ph.D.Chief Devel. OfficerMr. Bruce Greenberg CPA, M.B.A.Senior Vice President of Fin., Interim Chief Financial Officer & TreasurerDavid BurkeHead of Investor RelationsMr. Bruce Greenberg C.P.A., M.B.A.Senior Vice President of Fin., Interim Chief Financial Officer & Treasurer

NASDAQ : ALDX

Aldeyra Therapeutics

$1.66

-0.02-1.19%

At Close 4:00 PM

59.45

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Aldeyra Therapeutics, Inc. (ALDX) stock declined over -1.19%, trading at $1.66 on NASDAQ, down from the previous close of $1.68. The stock opened at $1.68, fluctuating between $1.63 and $1.72 in the recent session.

Stock Snapshot

1.68

Prev. Close

99.9M

Market Cap

1.63

Day Low

-2.96

P/E Ratio

-0.56

EPS (TTM)

-0.51

Cash Flow per Share

1.68

Open

60.18M

Number of Shares

1.72

Day High

96.88%

Free Float in %

2.02

Book Value

1.81M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	1.69	1.72	1.63	1.66	1.81M
Apr 01, 2026	1.71	1.87	1.68	1.68	4.53M
Mar 31, 2026	1.73	1.81	1.67	1.69	2.36M
Mar 30, 2026	1.76	1.78	1.68	1.68	1.88M
Mar 27, 2026	1.81	1.84	1.76	1.77	2.59M
Mar 25, 2026	1.98	2.02	1.76	1.85	4.53M
Mar 24, 2026	2.25	2.33	1.86	1.87	7.24M
Mar 23, 2026	1.88	2.32	1.82	2.23	7.04M
Mar 20, 2026	1.93	2.03	1.79	1.81	10.62M
Mar 19, 2026	1.39	1.85	1.37	1.83	11.76M
Mar 18, 2026	1.20	1.56	1.16	1.42	16.54M
Mar 17, 2026	1.12	1.51	1.07	1.24	51.45M
Mar 16, 2026	4.38	4.45	4.07	4.23	3.21M
Mar 13, 2026	4.69	4.72	4.01	4.13	3.36M
Mar 12, 2026	4.99	4.99	4.51	4.67	2.06M
Mar 11, 2026	5.10	5.10	4.74	4.94	1.62M
Mar 10, 2026	5.35	5.60	4.98	5.01	1.6M
Mar 09, 2026	4.80	5.30	4.75	5.26	1.36M
Mar 06, 2026	4.60	4.88	4.41	4.80	1.21M
Mar 03, 2026	5.50	5.52	5.06	5.11	862.99K

Contact Details

Lexington, MA 02421

United States

https://www.aldeyra.com 781 761 4904

About Company

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Stock Peers

REGN

-15.4-1.98%

Regeneron Pharmaceuticals, Inc.$761.85 ARGX

3.3+0.44%

argenx SE$746.42 UTHR

-5.46-0.96%

United Therapeutics Corporation$564.81 MDGL

17.05+3.22%

Madrigal Pharmaceuticals, Inc.$546.89 VRTX

-8.55-1.91%

Vertex Pharmaceuticals Incorporated$438.71 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-9.88-3.01%

Alnylam Pharmaceuticals, Inc.$318.85 PRAX

-8.9-2.79%

Praxis Precision Medicines, Inc.$310.38 KRYS

2.04+0.79%

Krystal Biotech, Inc.$260.95 ASND

1.01+0.44%

Ascendis Pharma A/S$229.25

Company Overview

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) closed at $1.66 USD, losing -$0.02 (-1.19%) from the previous close of $1.68. The stock is currently mid-range between its 52-week high and low $1.07 and $6.17. With a market capitalization of about $99.90 million, Aldeyra Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.33). Key stats such as the average daily volume over the past year has been around 2.87 million shares, volume is running light vs its 52-week average. Headquartered in Lexington, MA, Aldeyra Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Todd C. Brady, the company employs approximately 9 people and listed since May 02, 2014. Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases.

Technical Performance

ALDX has shown mixed momentum, gaining 15.01% over the past week and -9.7% over the past quarter, though year-to-date performance is down -8.3%. Short-term trend indicators are bearishly aligned (SMA20 4.13%, SMA50 9.93%, SMA200 16.72%). The stock’s 14-day RSI is 59.55 (neutral), while the ATR of 0.31 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -23.61% below its high and over 382.46% above its low. Average 10-day trading volume of 2.95 million shares is in line with the 3-month average of 2.87 million, indicating normal recent market interest.

Valuation Metrics

Aldeyra Therapeutics, Inc. trades at a P/E ratio of -2.95, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.26 suggesting the stock is closer to book value. The P/FCF stands at 0.0, also below market averages.

Dividend & Fair Value

Aldeyra Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.91. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Aldeyra Therapeutics, Inc. generated EPS of -$0.72 over the past year. Five-year average earnings growth is 15.99%. The latest quarter delivered EPS of -$0.13. The next quarter is forecast at -$0.16. Next year's EPS is expected at $48.38. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $2.00. The high target offers 502.41% upside. The low target suggests 20.48% downside. The mean target is $7.50. This offers 351.81% upside. Aldeyra Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -23.53%. The prior quarter beat by -23.81%. Over the last six quarters, Apple has recorded several small beats. These include 100.0% in September 26, 2024.

Shareholding & Insider Activity

Aldeyra Therapeutics, Inc. has 60.18 million shares outstanding. The public float is 48.56 million shares, elevated short interest at 11.02% of float. This equals 6.43 million shares. The short ratio is 5.28 days. Institutional investors hold 68.36% of the float. Insiders own 3.09%. EDELMAN JOSEPH holds 11.35 million shares, PERCEPTIVE ADVISORS LLC has 5.88 million shares and Brady Todd C has 1.47 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Aldeyra Therapeutics has not generated any revenue. Returns are negative, with ROA at -25.31% and ROE at -31.34%.
On valuation metrics, Aldeyra Therapeutics trades at a P/E of -2.95, P/S of 0.00 and P/B of 2.26. The current ratio is 2.58 and quick ratio is 2.58. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -888.25 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.35, supported by a cash flow-to-debt ratio of 1815512.34.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Aldeyra Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $262.78K (margin 0.00%). Operating income was - $42.79M (margin 0.0%). Net income was- $37.54M (EPS - $0.64).
The company ended the quarter with $142.82M in cash and short-term investments, a total debt of $15.66M, and net debt of - $127.17M. Total assets were $148.33M, with equity of $119.80M. Financials further reflected weakness, with operating cash flow of - $30.33M, free cash flow of - $30.33M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Aldeyra Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -72.89%, with price expected at $0.45 by April 16, 2026, within a range of $0.00 to $1.49 3-Month Outlook: Projected fall of -20.48%, reaching $1.32 by July 01, 2026, with a range of $1.10 to $1.56. 1-Year Outlook: Projected gain of 56.02%, with price at $2.59 by April 02, 2027, within a range of $0.00 to $4.54.

Key Takeaways

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares are flat -8.3% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Aldeyra Therapeutics, Inc. trading at a premium to the broader market with a P/E of -2.95. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $16.66, suggesting 903.61% upside. Our AI forecast model points to short-term weakness (-72.89% over two weeks), a medium-term fall (-20.48% over three months), and a longer-term gain (56.02% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Aldeyra Therapeutics, Inc. (ALDX) stock price?

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) stock price is $1.66 in the last trading session. During the trading session, ALDX stock reached the peak price of $1.72 while $1.63 was the lowest point it dropped to. The percentage change in ALDX stock occurred in the recent session was -1.19% while the dollar amount for the price change in ALDX stock was - $0.02.

ALDX's industry and sector of operation?

The NASDAQ listed ALDX is part of Biotechnology industry that operates in the broader Healthcare sector. Aldeyra Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ALDX?

Mr. Kelly Mizer
Vice President of Commercial Strategy & Operations
Dr. Todd C. Brady M.D., Ph.D.
Chief Executive Officer, Pres & Director
Dr. Stephen G. Machatha Ph.D.
Chief Devel. Officer
Mr. Bruce Greenberg CPA, M.B.A.
Senior Vice President of Fin., Interim Chief Financial Officer & Treasurer
David Burke
Head of Investor Relations
Mr. Bruce Greenberg C.P.A., M.B.A.
Senior Vice President of Fin., Interim Chief Financial Officer & Treasurer

How ALDX did perform over past 52-week?

ALDX's closing price is 55.14% higher than its 52-week low of $1.07 where as its distance from 52-week high of $6.18 is -73.12%.

How many employees does ALDX have?

Number of ALDX employees currently stands at 9.

Link for ALDX official website?

Official Website of ALDX is: https://www.aldeyra.com

How do I contact ALDX?

ALDX could be contacted at phone 781 761 4904 and can also be accessed through its website. ALDX operates from 131 Hartwell Avenue, Lexington, MA 02421, United States.

How many shares of ALDX are traded daily?

ALDX stock volume for the day was 1.81M shares. The average number of ALDX shares traded daily for last 3 months was 2.87M.

What is the market cap of ALDX currently?

The market value of ALDX currently stands at $99.90M with its latest stock price at $1.66 and 60.18M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	9
Beta	1.33
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ALDX Company Profile and Key Details

Aldeyra Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Valuation Metrics

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Key Takeaways

Price Forecast & Outlook